Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Phase II study of tosedostat in MDS

Sangmin Lee • 4 Jun 2021
EHA 2021
Myelodysplastic Syndromes Tosedostat

Sangmin Lee, MD, Weill Cornell Medicine, New York City, NY, gives an update on the Phase II IST-CTI-MDS study (NCT02452346) of tosedostat for patients with myelodysplastic syndromes (MDS). Dr Lee reports that tosedostat monotherapy was found to be active in patients with MDS with an overall response rate of 25% and a median overall survival of 15.6 months. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Sangmin Lee

1:45
Updates on the treatment of MDS
Sangmin Lee • 20 Oct 2021
1:07
Challenges in treating AML
Sangmin Lee • 20 Oct 2021
1:13
Rare blood diseases at LLM 2021
Sangmin Lee • 20 Oct 2021
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals